Acute Graft Versus Host Disease  >>  itacitinib (INCB039110)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
itacitinib (INCB039110) / Incyte
NCT02614612: Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD

Checkmark From trial for acute GVHD at ASH 2018 [screenshot]
Dec 2018 - Dec 2018: From trial for acute GVHD at ASH 2018 [screenshot]
Completed
1
31
US
Itacitinib (200 mg), INCB039110, Itacitinib (300 mg), prednisone or methylprednisolone (corticosteroids)
Incyte Corporation
Graft-versus-host Disease (GVHD)
06/16
08/18

Download Options